학술논문
456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S372-S373
Subject
Language
ISSN
0923-7534